GlassScriptPhysician profile
Caleb James Berg
NPI 1144908328
$4,020.73
in general payments reported to CMS, 2019-2025
20 companies · $2,368 in 2025
The $2,368 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $277 · 2024: $1,376 · 2025: $2,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,009 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,008.58 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $948.52 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $689.31 | 2023-2025 | Caplyta |
| Abbvie INC. | $468.55 | 2023-2025 | |
| Alkermes, INC. | $287.00 | 2023-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $266.49 | 2023-2025 | Rexulti |
| Alpha Cognition USA, INC. | $196.67 | 2025 | Zunveyl |
| Takeda Pharmaceuticals U.S.A., INC. | $175.87 | 2024-2025 | Trintellix |
| Axsome Therapeutics, INC. | $166.03 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $136.24 | 2023-2025 | Spravato |
| Tris Pharma INC | $116.20 | 2023-2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $96.89 | 2023-2025 | Xelstrym, Secuado |
| Almatica Pharma LLC | $80.40 | 2024-2025 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $72.75 | 2024-2025 | Rexulti |
| Livanova USA, INC. | $68.79 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Bausch Health US, LLC | $68.20 | 2023-2024 | Aplenzin |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $55.15 | 2025 | Adzenys Xr-Odt |
| Teva Pharmaceuticals USA, INC. | $38.89 | 2025 | Uzedy, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $37.69 | 2024-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $35.09 | 2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $16.00 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Berg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.